Precision BioSciences, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$154M
↑+13.2% +$18Mvs FY2024
Total Liabilities
$62M
↓-22.3% -$18Mvs FY2024
Equity
$92M
↑+63.6% +$36Mvs FY2024
Cash
$111M
↑+29.0% +$25Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $154M | $136M |
| Current Assets | $119M | $95M |
| Cash | $111M | $86M |
| ST Investments | $5M | $413K |
| Receivables | $0 | $229K |
| Inventory | $0 | $0 |
| Other Current | $3M | $8M |
| Non-Current Assets | $36M | $41M |
| PPE | $1M | $3M |
| Goodwill | $0 | $0 |
| Intangibles | $1M | $622K |
| Investments | $0 | $0 |
| Other Non-Current | $33M | $38M |
| Total Liab+Eq | $154M | $136M |
| Current Liab. | $9M | $15M |
| Accounts Payable | $296K | $1M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $3M |
| Other CL | $9M | $11M |
| Non-Current Liab. | $53M | $65M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $53M | $65M |
| Equity | $92M | $56M |
| Retained Earnings | $528M | $482M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · DTIL · Comparing FY2025 vs FY2024